Journey Medical (DERM) Receivables - Net (2020 - 2026)

Journey Medical (DERM) has reported Receivables - Net for 7 consecutive years, with $36.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net rose 131.69% year-over-year to $36.2 million; the trailing twelve-month figure through Jun 2026 stood at $36.2 million (up 131.69% YoY), and the FY2025 full-year result was $29.8 million, up 191.11% from the prior year.
• Receivables - Net grew to $36.2 million in Q2 2026 per DERM's latest filing, from $25.0 million in the prior quarter.
• Across five years, Receivables - Net topped out at $36.2 million in Q2 2026 and bottomed at $8.0 million in Q3 2023.
• Historically, Receivables - Net has averaged $20.4 million across 5 years, with a median of $18.0 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Receivables - Net sank 72.0% in 2023, then soared 191.11% in 2025.
• Over 5 years, Receivables - Net stood at $28.2 million in 2022, then sank by 46.04% to $15.2 million in 2023, then sank by 32.79% to $10.2 million in 2024, then jumped by 191.11% to $29.8 million in 2025, then climbed by 21.7% to $36.2 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $36.2 million, $25.0 million, and $29.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.